Hims shares jump on deal to offer Novo's Wegovy, Ozempic on its platform

March 9 (Reuters) - Hims & Hers' shares were up over 40% on Monday, after Novo Nordisk agreed to sell its blockbuster Wegovy ...

Hims & Hers shares surge after Novo Nordisk drops patent infringement case over compounded weight loss drugs

Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would ...
Fierce Pharma

Novo and Hims make nice, striking deal to sell Ozempic, Wegovy on Hims' telehealth platform

Hims & Hers and Novo Nordisk have officially laid down their swords. | The agreement marks the end of a longstanding public feud and allows Hims & Hers to sell Novo's branded Ozempic and Wegovy on its ...

Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit

By Stine Jacobsen and Maggie Fick COPENHAGEN, March 9 (Reuters) - Novo Nordisk has agreed to sell its blockbuster Wegovy and Ozempic drugs through U.S. telehealth company Hims & Hers' platform, the ...
24/7 Wall St.

Is Hims & Hers Really the Growth Stock to Buy That It Appears?

Hims & Hers Health (NYSE:HIMS) looked like a fallen growth star earlier this year. The telehealth platform was hammered by the FDA’s aggressive crackdown on compounded GLP-1 drugs, complete with ...